Europe Kidney Disease Market Drivers and Forecasts by 2027

The Europe kidney disease market is expected to reach US$ 37,311.1 million in 2027 from US$ 23,121.5 million in 2019. The market is estimated to grow with a CAGR of 6.2% from 2020-2027.

Kidney disease is also known as renal disease. It is caused due to the malfunctioning of the kidney. There are various types of kidney diseases including kidney stones, glomerulonephritis, urinary tract infections, and others. For the treatment and diagnosis of these types of diseases, different global and regional players are offering various products and services. The scope of the kidney disease market includes product, end-user, and region.

Germany Kidney Disease Market Revenue and Forecasts to 2027 (US$ MN)

Market Insights

The Rise in the Private Insurance Sector

Every country in the European Union allows private health insurance to operate alongside publicly-financed (statutory) health insurance, but there is enormous diversity in the role private health insuranceplays within the health system and in the size and functioning of different markets for private health insurance. It is difficult to think of private health insurancein isolation from statutory health coverage, particularly in the European Union, where private health insuranceis never the only primary source of content. The dominance of statutory coverage means that markets for private health insuranceare heavily shaped by the rules and arrangements of the publicly-financed part of the health system.For example, complimentary private health insurancecan cover services excluded from the statutory benefits package, as in Ireland, where it is combined with supplementary private health insuranceand covers about 50% of the population (The Competition Authority 2007). Or it may reimburse the costs of statutory user charges, as in Slovenia and France, where it covers over 70% and 92% of the population respectively (Albreht et al. 2002; Durand-Zaleski 2008).Germany has a favorable reimbursement policy. For instance, VELTASSA, a prescription medication used to treat high potassium levels in the blood (hyperkalemia), has now secured reimbursement in Germany, following the AMNOG process (Price negotiation and arbitration process) in May 2019. Thus, the rise in the private insurance sector is likely to create lucrative opportunities for market growth.

Product- Based Market Insights

Based on product,thekidney disease marketis segmented into diagnosis and treatment. The diagnosis segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Europe Kidney Disease Market, by Product – 2019 and 2027

End-User - Based Market Insights

Based on end-user, the kidney disease market, is segmented into hospitals, diagnostic laboratories, and others. The hospitals segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Europe Kidney Disease Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Product launches and approvals are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the kidney disease market adopt the expansion, collaboration, and product launch strategies to enlarge customer base across the world. These strategies allow the players to maintain their brand name globally. For instance,In July -2020, Bayer announced positive results from the Phase III FIDELIO-DKD study, assessing the efficacy and safety of finer none versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.

EUROPEKIDNEY DISEASE MARKET SEGMENTATION

By Product

• Diagnosis

o      Blood Tests

o      Urine Tests

o      Imaging Tests

o      Others

• Treatment

o      Dialysis

o      Others

o      Drug Class

• • • ACE Inhibitors
    • Angiotensin-II Receptor Blockers
    • Diuretics
    • Others

By End User

• Hospitals
• Diagnostic Laboratories
• Others

By Country

• Europe

o      Germany

o      UK

o      France

o      Spain

o      Italy

Company Profiles

• Abbott
• F. Hoffmann-La Roche Ltd
• AbbVieInc
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc
• Amgen Inc
• Sysmex Corporation
• Siemens AG

Europe Kidney Disease Market Report Scope

Europe Kidney Disease Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Kidney Disease Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.